EM2308C "Translating Enzyme Biologics for Mineralization and Autoimmune Disease into the clinic - an Academic Perspective" (IM GR-081123)
Purpose and Overview
This lecture will cover examples of enzyme biologics developed in academia and then translated bench to bedside into the clinic. One example will be an early-stage asset, and a second example a late-stage asset about to begin phase 3 clinical trials. Specifically, enzyme biologics for mineralization autoimmune diseases occurring in the rare disease and general medical population will be discussed, beginning with disease pathophysiology, then the design and optimization of biologics to ameliorate disease progression and severity, and concluding with the use of animal models to validate efficacy.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Understand the relationship between the development of lupus autoimmunity, loss of tolerance to self-DNA in lupus, and the innate immune system.
- Understand the phenotype of patients with 'paradoxical mineralization disorder' and identify rare and common mineralization diseases in which paradoxical mineralization occurs.
- Understand the differing risk and efficacy profiles for small molecule and biologic therapeutic drug development for rare and common disease.
Demetrios Braddock, M.D., Ph.D.
Associate Professor of Pathology
Brady Memorial Lab
Yale University School of Medicine
- 1.00 AMA